IP Library Granted Patent US 9,517,355
Granted Patent B2
US 9,517,355 · App. 14/455,497 · Granted Dec 13, 2016

Near-infrared enhancement of circadian and ultradian spatiotemporal cellular coordination

Inventor: Eric Bornstein (Woodmere, NY)
Assignee: NOMIR MEDICAL TECHNOLOGIES, INC.
A61N5/0613A61N2005/0626A61N2005/0659
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,517,355
App. No.
14/455,497
Granted
Dec 13, 2016
Kind
B2
Abstract

A method is disclosed of providing photo-chrono-therapy to a wound site in a human or animal subject, the method including: determining or receiving subject circadian and/or ultradian cycle information indicative of a biological rhythm(s) of the subject; and based on the subject cycle information, delivering a photo-chrono-dose of infrared treatment light to the wound site with wavelengths within at least one infrared wavelength range and having a dosimetry configured to promote healing at the wound site.

Claims (30)

1. A method of providing photo-chrono-therapy to a wound site in a human or animal subject, the method comprising:

determining or receiving subject circadian and/or ultradian cycle information indicative of a biological rhythm(s) of the subject; and

based on the subject cycle information, delivering a photo-chrono-dose of infrared treatment light to the wound site with wavelengths within at least one infrared wavelength range and having a dosimetry configured to promote healing at the wound site.

2. The method of claim 1 , wherein

the subject cycle information comprises circadian information indicative of a circadian rhythm of the subject, and

delivering the photo-chrono-dose comprises delivering the treatment light at a time corresponding to one or more selected phases in a cell-cycle of the subject based on the circadian information.

3. The method of claim 2 , wherein the one or more selected phases comprise a G1 or early S-phase of the cell-cycle.

4. The method of claim 1 , wherein the wound site comprises an internal peripheral portion and an external peripheral portion each having a wound margin and a central portion, and wherein delivering a photo-chrono-dose of infrared treatment light to the wound site comprises preferentially delivering light to either or both of the peripheral portions of the wound singly or simultaneously.

5. The method of claim 4 , further comprising stimulating migration of eukaryotic cells from the peripheral portion of the wound site to the central portion of the wound site.

6. The method of claim 5 , wherein the eukaryotic cells comprise at least one of fibroblasts and keratinocytes.

7. The method of claim 6 , wherein stimulating migration of eukaryotic cells comprises generating spatio-temporal photo-taxis in the eukaryotic cells.

8. The method of claim 7 , wherein generating spatio-temporal photo-taxis in the eukaryotic cells comprises causing optically mediated mechanotransduction at cell membranes to stimulate directed lamellopod or pseudopod creation in the cells.

9. The method of claim 8 , wherein the optically mediated mechanotransduction causes forces at the cell membrane that reinforce endogenous membrane waves in the cells.

10. The method of claim 9 , wherein preferentially delivering light to the internal or external peripheral portion comprises delivering the light with a substantially annular spatial distribution.

11. The method of claim 10 , the light with a substantially annular spatial distribution comprises delivering the light as a ring of spots at the wound cite.

12. The method of claim 1 , wherein the subject cycle information comprises ultradian information indicative of an ultradian rhythm of the subject, and further comprising modulating the treatment light delivered to the wound site based on the ultradian information.

13. The method of claim 12 , wherein the ultradian information comprises information indicative of a pulse or heartbeat in the subject.

14. The method of claim 13 , further comprising receiving at least one sensor signal indicative of the ultradian information.

15. The method of claim 14 , wherein the sensor signal comprises a pulse oximeter signal or an electrocardiogram signal.

16. The method of claim 1 , wherein delivering the photo-chrono-dose of infrared treatment light comprises:

generating near-infrared optical radiation with wavelengths within a first wavelength range of 850 nm to 900 nm or a second wavelength range of 910 nm to 950 nm; and

delivering the near-infrared optical radiation to the wound site with a power density at the treatment sight in the range of 0.015-1.0 W/cm^2 and an energy density in the range of 0.5-3500 J/cm^2.

17. The method of claim 16 , wherein the near-infrared optical radiation comprises radiation in the first and second wavelength ranges.

18. The method of claim 16 , comprising:

stimulating collagen synthesis at the wound site by delivering mid-infrared optical radiation to the wound site;

wherein delivering mid-infrared optical radiation to the wound site comprises:

generating mid-infrared optical radiation substantially in a third wavelength range of 6.35 microns to 6.55 microns; and

delivering the mid-infrared optical radiation to the wound site with a power density at the treatment sight in the range of 0.01-1.0 W/cm^2 and an energy density in the range of 0.5-3500 J/cm^2.

19. The method of claim 1 , further comprising applying the near infrared optical radiation to stimulate leptin production from adipose tissue in the external periphery of the wound site.

20. The method of claim 1 , further comprising intentionally creating a wound at the wound site.

Assignments (2)
SECURITY INTEREST Recorded Nov 24, 2015
From: NOMIR MEDICAL TECHNOLOGIES, INC.
To: GOODKIN AS AGENT FOR VARIOUS NOTE HOLDERS, RICHARD P.
Reel/Frame 037131/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2014
From: BORNSTEIN, ERIC
To: NOMIR MEDICAL TECHNOLOGIES, INC.
Reel/Frame 034151/0097 →
Continuity (5)
Continuation In Part PCTUS2013025624 · Feb 11, 2013
Provisional Application 61739331 · Dec 19, 2012
Provisional Application 61637681 · Apr 24, 2012
Provisional Application 61597497 · Feb 10, 2012
Related Publication 20150025599A1 · Jan 22, 2015